Director, Clinical-Translational Science
AdvanCell · AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.
Brisbane, QLD, AustraliaTranslational Medicine51-100 employeesPosted 72 days ago
Series D · $315Mraised 4 months agoled by Eli Lilly, Alpha Wave Global, Catalio Capital Management
This board only lists companies whose most recent round closed in the last 180 days.
The Director, Clinical-Translational Science will provide scientific leadership across AdvanCell’s biobanking and clinical translational research activities, supporting the delivery of translational research aligned with clinical development objectives.
The role will provide scientific oversight and technical support for sample processing, storage, data management and analysis, ensuring all activities are conducted to the appropriate quality, safety and regulatory standards. The role will lead and coordinate translational research initiatives using clinical samples and data to identify and develop novel biomarkers and research, working collaboratively with AdvanCell’s cross-functional teams and external partners.
It will also support the development and expansion of in-house research capabilities, scientific interpretation and communication, and the translation of research findings into insights that inform clinical development and research decision-making.
Apply on AdvanCell’s site
Applications go straight to the employer. VCBacked does not sit between you and the company.